NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...

分组1 - Royalty Pharma plc (RPRX) reported strong financial performance in 2025, with double-digit growth in both Royalty Receipts and Portfolio Receipts, leading to excellent returns on invested capital [1] - The company has maintained effective capital deployment strategies, contributing to its financial success [1] 分组2 - The focus of the analysis is on identifying promising biotechnology companies that are innovating through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The approach emphasizes evaluating the scientific basis of drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

分组1 - Royalty Pharma plc (RPRX) reported strong financial performance in 2025, with double-digit growth in both Royalty Receipts and Portfolio Receipts, leading to excellent returns on invested capital [1] - The company has maintained effective capital deployment strategies, contributing to its financial success [1] 分组2 - The analyst emphasizes a focus on identifying promising biotechnology companies that innovate through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The approach combines scientific expertise with financial and market analysis to deliver research that is both technically sound and investment-driven [1] - The goal is to provide insights that help investors understand opportunities and risks in the biotech sector, which is characterized by the potential for significant returns through breakthrough science [1]

Teva Pharmaceutical Industries Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Date of Conference**: February 13, 2026 - **Key Speaker**: Dr. Eric Hughes, Chief Medical Officer Core Industry Focus - **Industry**: Pharmaceutical, specifically in immunology and drug development Key Points and Arguments Immunology R&D Efforts - Teva is focusing on validated molecular targets in its immunology R&D, including TSLP/IL-13-directed treatments [1][2][3] - The company has a strong antibody and protein engineering group, enhancing its capabilities in developing biosimilars and innovative drugs [4][5] Targeted Approaches - The company is exploring various combinations of molecular targets to increase the probability of success in drug development [5][6] - Teva is agnostic regarding the source of innovation, whether internal or through business development and collaborations [8][10] IL-15-Directed Antibody (408) - Teva is accelerating its IL-15-directed antibody program, targeting vitiligo and celiac disease with timelines set for 2031 and 2034, respectively [12][13] - The company has secured up to $500 million in R&D funding from Royalty Pharma for the vitiligo program, emphasizing the high costs associated with drug development [19][21] Clinical Development Insights - The phase IIb study for vitiligo will require a safety database of approximately 1,400 patients for FDA approval [22] - The company aims to differentiate its IL-15 treatment from existing therapies by potentially offering a quarterly dosing regimen, contrasting with daily treatments of current options [37][39] Mechanistic Rationale - The mechanism of action for IL-15 in vitiligo involves blocking signals that maintain CD8 positive T-cells, which destroy melanocytes [31][33] - In celiac disease, IL-15 is linked to the proliferation of anti-gut lining cells, and blocking it may prevent damage to the gut lining [45][47] Competitive Landscape - Teva's IL-15 antibody is considered more potent than competitors, with a lower rate of anti-drug antibodies [50] - The company is exploring additional indications for its IL-15 treatment, including atopic dermatitis and alopecia areata [51] Future Developments - Teva plans to submit an IND for the TSLP/IL-13 combination by the end of the year, indicating a proactive approach to advancing its pipeline [85] Additional Important Insights - The company acknowledges the high costs of drug development, with $500 million being a reasonable estimate for a vitiligo program [21] - Safety profiles of new treatments are a significant concern, with IL-15 showing promising tolerability compared to existing JAK inhibitors [44] This summary encapsulates the key discussions and insights from the Teva Pharmaceutical Industries conference, highlighting the company's strategic focus on immunology and its innovative approaches to drug development.

AnaptysBio Conference Call Summary Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Date**: February 12, 2026 Key Points Separation of Royalty Pharma and Biopharma - The separation of the royalty company and the biopharma business is a top priority, targeted for completion in Q2 2026, though it may extend beyond April 1 [2][4] - The royalty company will focus on recognizing the value of commercial entities with low operational expenses, driven by the growth of Jemperli and Imsidolimab [4][5] Financial Position - AnaptysBio started the year with $310 million in cash, approximately $11 per share [7] - The company plans to allocate sufficient cash to the biopharma business to support operations through 2027, potentially extending cash reserves into 2028 [7][8] Jemperli Performance - Jemperli reported Q4 sales of $343 million, reflecting a 13% quarter-over-quarter growth [12] - It is positioned as a best-in-class PD-1 antagonist, with significant growth potential driven by multiple indications, including rectal cancer and MSI-H colon cancer [13][15] - Analysts have not fully recognized Jemperli's growth potential, with some assigning negative growth rates despite its rapid sales increase [14] ANB033 and Celiac Disease - ANB033, a CD122 antagonist, is being developed for celiac disease, targeting a market with over 2 million patients in the U.S. [21][22] - The study design includes a gluten challenge with a focus on histological outcomes and patient-reported outcomes [24][25] - Data readout is expected in Q4 2026, with enrollment having started in Q4 2025 [27][28] Eosinophilic Esophagitis (EoE) - The company is also advancing a program for EoE, with a focus on reducing eosinophils and improving patient-reported outcomes [52] - The market for EoE is significant, with dupilumab generating approximately $2 billion annually [48] Rosnilimab Development - Rosnilimab has shown promising results in rheumatoid arthritis, with plans to advance it through partnerships rather than using balance sheet cash [55][56] - An update on the phase 3 advancement is expected in the first half of 2026 [54] BDCA2 Modulator (ANB101) - ANB101 is in phase 1 development, with potential applications in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) [60] - The company is monitoring Biogen's trials for insights on advancing ANB101 [61] Legal Considerations - Ongoing litigation with GSK regarding contractual issues could impact the royalty business, with potential for the drug to revert back to AnaptysBio [65][66] Conclusion - AnaptysBio is positioned for significant developments in 2026, with multiple catalysts including the separation of its businesses, Jemperli's growth, and advancements in its clinical programs [68]

Group 1 - The core viewpoint is that Royalty Pharma plc (NASDAQ: RPRX) is viewed positively following its Q4 and full-year 2025 results, indicating solid execution and an attractive entry point for investors [1] - The stock is supported by resilient figures and is being analyzed by buy-side hedge professionals who focus on fundamental, income-oriented, long-term analysis across global developed markets [1]

Financial Performance - In 2025, the company generated $3.3 billion in Portfolio Receipts, excluding $511 million from the sale of MorphoSys Development Funding Bonds[21] - The company announced transactions with a total potential value of $4.7 billion and deployed $2.6 billion in cash for acquiring royalties and contractual receipts[21] - The biopharmaceutical royalty market reached $10.0 billion in transaction value in 2025, a 40% increase from the average of $7.1 billion over the previous five years[32] - The company executed transactions with an aggregate announced value of $19.4 billion from 2020 to 2025, capturing approximately 48% market share of all royalty transactions during this period[35] - As of December 31, 2025, the portfolio included royalties on 16 therapies generating over $1 billion in sales, with 7 therapies exceeding $3 billion[39] - The estimated weighted average duration of the portfolio's royalties is approximately 13 years, with significant products protected by long patent lives[41] - In 2025, the company paid dividends and distributions of $511.9 million and repurchased $1.2 billion of shares[42] Investment Strategy - The company has a success rate of 90% for development-stage acquisitions, with $6.5 billion of these products already approved[45] - The company’s investment approach is agnostic to therapeutic area and treatment modality, allowing for broad acquisition opportunities across the biopharmaceutical industry[47] - The company focuses on acquiring royalties on approved products and development-stage candidates with strong proof of concept data, mitigating development risk[47] Revenue Projections - The company expects 2025 portfolio receipts to reach $3.254 billion, with end market sales projected at $36.5 billion across its approved products[51] - The cystic fibrosis franchise is projected to generate $917 million in royalty receipts, with end market sales of $11.725 billion in 2025[51] - Trelegy is anticipated to contribute $332 million in royalties, with end market sales of $3.912 billion[51] - Tysabri is expected to yield $250 million in royalties, with end market sales of $1.665 billion[51] Royalty Structures - The company has a blended royalty rate of slightly over 9% for the cystic fibrosis franchise, with ownership percentages of 86.8%[55] - The royalty rate for Evrysdi is tiered, starting at 8% on the first $500 million and going up to 16% on sales exceeding $2 billion[55] - The company acquired a royalty interest in Alnylam's Amvuttra for $310 million, which is an approved RNAi therapeutic[64] - The portfolio includes development-stage product candidates, with Ampreloxetine expected to have Phase 3 data available in Q1 2026[62] - The company has a perpetual royalty interest in Tysabri, with tiered payments of 18% on the first $2 billion and 25% on sales exceeding $2 billion[55] - Spinraza royalties will revert to Ionis after reaching aggregate royalties of $475 million or $550 million, depending on specific events[60] Funding and Financial Commitments - As of December 31, 2025, the company has funded a total of $275 million under the Cytokinetics Commercial Launch Funding, with total repayments expected to reach $450 million[65] - The company anticipates receiving $100 million if the Phase 3 trial of omecamtiv mecarbil is positive and FDA approval is granted, along with potential tiered royalties[66] - If TEV-'749 is approved by the FDA, the company will receive $100 million plus tiered royalty payments based on worldwide sales[67] - The company plans to provide $250 million in funding over six quarters for Biogen's R&D, contingent on meeting certain regulatory milestones[67] Market Competition and Risks - The company faces significant competition in acquiring biopharmaceutical royalties, with potential acquirers including larger biopharmaceutical companies and institutional investors[68] - The biopharmaceutical industry is highly competitive, and products may become obsolete due to new alternatives or improvements, impacting revenue streams[69] Workforce and Governance - As of December 31, 2025, the company had 100 employees, with no union representation, and completed the acquisition of its former external manager[76] - The workforce is composed of 48% women and approximately 36% ethnically diverse individuals, reflecting the company's commitment to diversity[77] - The company maintains robust governance policies to ensure compliance with regulatory standards and ethical practices[72] Sustainability and Financial Position - The company is focused on sustainability practices to minimize environmental impact and track its carbon footprint[75] - The company held cash and cash equivalents of $618.7 million as of December 31, 2025, with $235.1 million in cash and $383.6 million in interest-bearing money market funds[388] - The company has a $1.8 billion Revolving Credit Facility, a $350 million Uncommitted Credit Facility, and a $380 million Term Loan, with no outstanding borrowings on the Revolving and Uncommitted Credit Facilities as of December 31, 2025[390] Financial Asset Management - As of December 31, 2025, Vertex accounted for 32% of the current portion of financial royalty assets, making it the largest individual marketer and payor of royalties[391] - The company is subject to interest rate sensitivity due to its investments in marketable securities, which primarily bear variable interest rates[386] - The company has not experienced significant losses in the collection of income or revenue from its royalty assets or available for sale debt securities to date[392] - The company’s investment policy focuses on capital preservation and liquidity needs, maintaining excess cash in money market funds and investment-grade securities[389] - The company is exposed to foreign currency exchange risk, particularly with royalties paid in currencies other than U.S. dollars, such as Euro and British pound[387] - The company follows established risk management policies, including the use of derivative financial instruments to manage interest rate and foreign currency risks[386] Regulatory and Legal Considerations - The company’s ability to continue its business may be adversely affected if the SEC changes its interpretation regarding royalty receivables[84] - The company was incorporated under the laws of England and Wales on February 6, 2020, and is a holding company with a controlling equity interest in Royalty Pharma Holdings Ltd[85]

Financial Data and Key Metrics Changes - Royalty Pharma achieved strong double-digit growth in both portfolio receipts and royalty receipts, with portfolio receipts growing 18% in Q4 and 16% for the full year [25][5] - Return on invested capital was 15.8% and return on invested equity was 22.8% for the year, reflecting strong returns [28][5] - The company raised its guidance three times during the year, delivering results slightly above the top end of the most recent update [5][6] Business Line Data and Key Metrics Changes - The company deployed $2.6 billion in capital for the year, with 67% of investments in approved products and 33% in development stage therapies [18][31] - Synthetic royalty transactions reached a record value of $4.7 billion in 2025, exceeding traditional royalties for the first time [15][61] - Royalty receipts from key products like Voranigo, Trelstar, and Tremfya contributed significantly to growth, with minimal contribution from new acquisitions [27][25] Market Data and Key Metrics Changes - The biopharma market reached $10 billion in announced transaction value for the first time, with a strong growth trajectory observed [9] - The average annual transaction value in the biopharma market nearly doubled over the past five years compared to the previous five years [9] Company Strategy and Development Direction - Royalty Pharma aims to be the premier capital allocator in life sciences, focusing on consistent compounding growth and shareholder value creation [5][6] - The company is excited about expanding its team and platform in China, indicating a strategic focus on international growth [36][73] - The internalization of the external manager is expected to enhance governance and reduce costs, aligning intellectual capital with the royalty portfolio [7][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business, highlighting the potential for significant value creation from the development stage pipeline [11][12] - The company anticipates continued growth driven by the increasing recognition of biopharma royalties and the demand for capital in life sciences [10][11] - Future guidance for 2026 indicates expected growth in royalty receipts of 3%-8%, despite anticipated losses from exclusivity expirations [32][35] Other Important Information - The company returned $1.7 billion to shareholders through share repurchases and dividends, with a 7% increase in dividends announced for Q1 2026 [8][31] - The company expects to maintain a high level of cash conversion and efficiency, with operating costs projected to decrease significantly in 2026 [33][25] Q&A Session Summary Question: Sustainability of dividends and buybacks - Management indicated that capital allocation will be based on the relative attractiveness of royalty opportunities versus stock price value, with a current bias towards royalties [40][42] Question: Involvement in private companies and capital markets - Management is open to exploring high-quality assets in private companies and remains focused on investing in high-quality pharmaceutical products [44][42] Question: Performance of Alyftrek and patient conversion - Management noted that the conversion to Alyftrek has been gradual but consistent, with expectations for continued contributions from the cystic fibrosis franchise [48][52] Question: General medicine and cardiometabolic disease categories - Management expressed excitement about opportunities in the cardiovascular space, emphasizing a diverse approach to drug delivery formats [59][54] Question: Synthetic royalties trend - Management is optimistic about the growth of synthetic royalties, noting increased awareness and demand for this funding model [61][62] Question: Lp(a) class of drugs and trial outcomes - Management remains enthusiastic about the Lp(a) class, with no change in outlook despite trial delays, awaiting results from Novartis [63][64] Question: Underappreciated assets in the portfolio - Management highlighted significant potential in the pipeline, with several products expected to deliver substantial value [70][69] Question: China opportunity and strategic focus - Management is excited about the growing opportunity in China, with plans to expand the team and platform in the region [73][72]

Financial Data and Key Metrics Changes - Royalty Pharma achieved strong double-digit growth in both portfolio receipts and royalty receipts, with portfolio receipts growing 16% for the year and royalty receipts growing 13% [5][24] - The company maintained a return on invested capital of 15.8% and a return on invested equity of 22.8% for the year [5][27] - The company returned $1.7 billion to shareholders, including $1.2 billion in share repurchases and over $500 million in dividends, with a 7% increase in dividends announced for the first quarter of 2026 [7][29] Business Line Data and Key Metrics Changes - The company reported strong performance from key products such as Voranigo, Trelstar, TREMFYA, and the cystic fibrosis franchise, contributing to the growth in royalty receipts [26] - In 2025, synthetic royalty transactions reached a record value of $4.7 billion, significantly higher than previous years, indicating a growing trend in this funding modality [14][15] Market Data and Key Metrics Changes - The biopharma market reached $10 billion in announced transaction value for the first time in 2025, with a strong growth trajectory observed over the past five years [8] - The company noted that the demand for capital in life sciences is increasing, driven by the recognition of the benefits of biopharma royalties [9] Company Strategy and Development Direction - Royalty Pharma aims to be the premier capital allocator in life sciences, focusing on consistent compounding growth and shareholder value creation [5][10] - The company plans to continue expanding its capital deployment strategy, with a focus on high-quality assets and innovative therapies [12][16] - The internalization of the external manager is expected to enhance governance and reduce costs, further supporting the company's strategic goals [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to deliver consistent returns, even in uncertain market conditions [10][11] - The guidance for 2026 indicates expected growth in royalty receipts of 3%-8%, reflecting the strength of the existing portfolio [30][33] - Management highlighted the potential for significant value creation from the development stage pipeline, with multiple pivotal readouts expected in the near term [20][22] Other Important Information - The company achieved its five-year capital deployment target of $10 billion-$12 billion one year ahead of schedule [10][17] - The company has a robust pipeline of 20 development-stage therapies, with estimated combined peak sales of over $43 billion, translating to over $2.1 billion in peak annual royalties [22] Q&A Session Summary Question: Sustainability of dividends and buybacks in 2026 - Management indicated that capital allocation will be based on the relative attractiveness of royalty opportunities versus stock price value, with a focus on returning capital to shareholders while prioritizing royalty investments [38][40] Question: Involvement in private companies and capital markets - Management stated that they are open to investing in high-quality assets within private companies and are excited about the growth of opportunities in the sector [42] Question: Performance of ALYFTREK and patient conversion - Management noted that the conversion to ALYFTREK has been gradual but consistent, with expectations for continued contributions from the cystic fibrosis franchise [45][50] Question: General medicine and cardiometabolic disease categories - Management expressed excitement about opportunities in the cardiovascular and cardiometabolic markets, emphasizing a diversified approach to drug delivery formats [51][52] Question: Future of synthetic royalties - Management is optimistic about the continued growth of synthetic royalties, highlighting their advantages over traditional financing methods [56][59] Question: Lp(a) class of drugs and trial outcomes - Management remains enthusiastic about the Lp(a) class and is awaiting results from ongoing trials, with no change in their positive outlook [60][61] Question: Underappreciated assets in the portfolio - Management highlighted the significant potential for value creation in the pipeline, with several products expected to deliver strong returns [66][68] Question: China opportunity and strategic focus - Management is excited about the growing opportunity in China and is looking to expand their team and platform in the region [69][71] Question: Teva's IL-15 asset and mid-stage investments - Management explained that the investment in Teva's asset was driven by the unmet need in the vitiligo market and emphasized their flexible investment structure [76][78] Question: Growth potential of VORANIGO - Management expressed strong confidence in the growth trajectory of VORANIGO, anticipating it to become a blockbuster product [79][80]

Financial Data and Key Metrics Changes - Royalty Pharma achieved strong double-digit growth in both portfolio receipts and royalty receipts, with portfolio receipts growing 16% for the year and royalty receipts growing 13% [4][23] - The company maintained a return on invested capital of 15.8% and a return on invested equity of 22.8% for the year [4][26] - The company returned $1.7 billion to shareholders, including $1.2 billion in share repurchases and over $500 million in dividends, with a 7% increase in dividends announced for Q1 2026 [6][28] Business Line Data and Key Metrics Changes - The cystic fibrosis franchise, along with products like Voranigo, Trelstar, and Tremfya, were key drivers of growth, contributing significantly to the overall increase in royalty receipts [25] - The company executed eight transactions for nine therapies in 2025, with an announced value of $4.7 billion, reflecting a disciplined approach to capital allocation [12][17] Market Data and Key Metrics Changes - The biopharma market reached $10 billion in announced transaction value for the first time, with a strong growth trajectory observed over the past five years [8] - Synthetic royalty transactions set a new record in 2025, with a market value increase of about 50% compared to the previous year, totaling $4.7 billion [14][15] Company Strategy and Development Direction - Royalty Pharma aims to be the premier capital allocator in life sciences, focusing on consistent compounding growth and shareholder value creation [4][5] - The company is excited about expanding its team and platform in China, indicating a strategic focus on international growth opportunities [34][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business, highlighting the potential for significant value creation from the development stage pipeline [10][22] - The company anticipates a growth rate of 3%-8% in royalty receipts for 2026, reflecting strong underlying momentum despite expected challenges from loss of exclusivity for certain products [29][33] Other Important Information - The internalization of the external manager in 2025 is expected to yield cost savings and improved governance [5][6] - The company achieved its five-year capital deployment target of $10 billion-$12 billion one year ahead of schedule [10][17] Q&A Session Summary Question: Sustainability of dividends and buybacks in 2026 - Management indicated that capital allocation will be based on the relative attractiveness of royalty opportunities versus stock price value, with a current bias towards royalties [39][41] Question: Involvement in private companies and capital markets - Management is open to exploring high-quality pharmaceutical products within private companies and sees growth opportunities regardless of market conditions [43][44] Question: Performance of Alyftrek and patient conversion - Management noted that the conversion to Alyftrek has been gradual but steady, with expectations for continued contributions from the cystic fibrosis franchise [47][51] Question: General medicine and cardiometabolic disease categories - Management expressed excitement about opportunities in general medicine and indicated a flexible approach to drug delivery formats based on patient needs [53][54] Question: Future of synthetic royalties - Management is optimistic about the growth of synthetic royalties, noting increased awareness and demand for this funding model [57][60] Question: Lp(a) class of drugs and trial outcomes - Management remains enthusiastic about the Lp(a) class and is awaiting results from ongoing trials, emphasizing the potential for significant royalties [61][62] Question: Underappreciated assets in the portfolio - Management highlighted the significant potential for value creation in the pipeline, particularly in products like solanezumab and frexalimab [68][69] Question: China opportunity and transaction pipeline - Management is excited about the growing opportunity set in China and is actively pursuing expansion in that market [70][72]